Press coverage about Gilead Sciences (NASDAQ:GILD) has been trending somewhat positive on Saturday, Accern Sentiment reports. Accern identifies positive and negative press coverage by monitoring more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Gilead Sciences earned a news impact score of 0.11 on Accern’s scale. Accern also gave news stories about the biopharmaceutical company an impact score of 47.2279393349918 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.
These are some of the media headlines that may have effected Accern Sentiment’s scoring:
Gilead Sciences (GILD) traded up $0.75 during trading hours on Friday, hitting $73.77. The stock had a trading volume of 7,698,200 shares, compared to its average volume of 9,360,261. The company has a quick ratio of 4.74, a current ratio of 3.68 and a debt-to-equity ratio of 1.10. Gilead Sciences has a fifty-two week low of $63.76 and a fifty-two week high of $86.27. The firm has a market cap of $95,383.76, a P/E ratio of 7.62, a PEG ratio of -1.22 and a beta of 1.13.
Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings results on Thursday, October 26th. The biopharmaceutical company reported $2.27 EPS for the quarter, topping the consensus estimate of $2.13 by $0.14. The firm had revenue of $6.51 billion for the quarter, compared to analyst estimates of $6.40 billion. Gilead Sciences had a return on equity of 57.15% and a net margin of 42.22%. Gilead Sciences’s revenue for the quarter was down 13.2% on a year-over-year basis. During the same period in the previous year, the company posted $2.75 EPS. equities analysts forecast that Gilead Sciences will post 8.53 EPS for the current year.
The business also recently disclosed a quarterly dividend, which will be paid on Thursday, December 28th. Investors of record on Friday, December 15th will be paid a dividend of $0.52 per share. The ex-dividend date of this dividend is Thursday, December 14th. This represents a $2.08 dividend on an annualized basis and a yield of 2.82%. Gilead Sciences’s payout ratio is currently 23.69%.
A number of equities research analysts have recently commented on GILD shares. Berenberg Bank set a $96.00 price target on shares of Gilead Sciences and gave the company a “buy” rating in a report on Thursday, October 19th. Royal Bank of Canada started coverage on shares of Gilead Sciences in a research report on Thursday, September 14th. They set an “outperform” rating and a $94.00 price objective on the stock. J P Morgan Chase & Co set a $85.00 price target on shares of Gilead Sciences and gave the stock a “buy” rating in a research report on Wednesday, October 25th. Robert W. Baird reiterated an “outperform” rating and issued a $87.00 price target on shares of Gilead Sciences in a research report on Tuesday, August 29th. Finally, Leerink Swann reissued a “hold” rating and issued a $74.00 price objective on shares of Gilead Sciences in a research note on Tuesday, July 25th. One research analyst has rated the stock with a sell rating, eleven have issued a hold rating, nineteen have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The company has an average rating of “Buy” and an average price target of $85.92.
COPYRIGHT VIOLATION WARNING: This news story was originally published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this news story on another publication, it was illegally stolen and reposted in violation of United States and international copyright & trademark law. The correct version of this news story can be viewed at https://www.dispatchtribunal.com/2017/11/11/somewhat-favorable-news-coverage-somewhat-unlikely-to-impact-gilead-sciences-gild-stock-price.html.
In related news, insider John C. Martin sold 73,333 shares of the stock in a transaction dated Wednesday, November 1st. The stock was sold at an average price of $75.13, for a total value of $5,509,508.29. Following the completion of the sale, the insider now directly owns 3,070,099 shares of the company’s stock, valued at approximately $230,656,537.87. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, EVP Gregg H. Alton sold 50,000 shares of the stock in a transaction dated Wednesday, August 30th. The stock was sold at an average price of $79.00, for a total value of $3,950,000.00. Following the completion of the sale, the executive vice president now directly owns 113,237 shares of the company’s stock, valued at $8,945,723. The disclosure for this sale can be found here. In the last three months, insiders sold 446,819 shares of company stock valued at $36,269,486. Company insiders own 1.30% of the company’s stock.
Gilead Sciences Company Profile
Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.
Receive News & Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.